ALLO

Allogene Therapeutics, Inc. [ALLO] Stock Forecast

Buy or Sell ? Support and Resistance

What is MACD and how to read it?

How RSI can help?
RSI : 000

ALLO Stock Summary

Top ALLO Correlated Resources

ALLO


Top 10 Correlated Stocks

ALLO


In the News

03:27 04 Dec 2022 ALLO

Allogene: Pioneering Allogeneic CAR-T Developer With No Near-Term Catalysts

Allogene Therapeutics, Inc. has an excellent pedigree and superior science. However, with it being a leader in a difficult field, investing in Allogene Therapeutics, Inc. here is tough.

11:18 04 Dec 2022 ALLO

Top 10 most-shorted stocks as of November 2022

The difficult state of the macroeconomic environment in 2022 has had a negative impact on the performance of a number of equity investments. Worries about a recession and a bearish attitude among investors have been especially unsettling for companies with weak financial positions.

08:30 04 Dec 2022 ALLO

Allogene Therapeutics To Host Research & Development Showcase and Participate in Five Upcoming Investor Conferences

SOUTH SAN FRANCISCO, Calif., Nov. 09, 2022 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer will host a Research & Development Showcase to provide a comprehensive overview of its CD19 and BCMA programs on November 29, 2022. The Company will also participate in five upcoming investor conferences.

02:18 04 Dec 2022 ALLO

Allogene (ALLO) Reports Narrower-Than-Expected Loss in Q3

Allogene's (ALLO) third-quarter earnings beat estimates, but sales miss the mark. ALLO will host an R&D showcase later this month and discuss updated clinical data on its pipeline candidates.

11:30 04 Dec 2022 ALLO

Allogene Therapeutics, Inc. (ALLO) Q3 2022 Earnings Call Transcript

Allogene Therapeutics, Inc. (NASDAQ:ALLO ) Q3 2022 Earnings Conference Call November 2, 2022 5:00 PM ET Company Participants Christine Cassiano - CCO David Chang - President and CEO Rafael Amado - EVP, Research & Development and CMO Eric Schmidt - CFO Conference Call Participants Andrea Tan - Goldman Sachs Michael Yee - Jefferies Tyler Van Buren - Cowen Asthika Goonewardene - Truist Raju Prasad - William Blair Reni Benjamin - JMP Securities Mark Breidenbach - Oppenheimer John Newman - Canaccord Genuity Michael Schmidt - Guggenheim Partners Luca Issi - RBC Capital Markets Jason Gerberry - Bank of America Kalpit Patel - B. Riley David Dai - SMBC Jack Allen - Baird Brian Cheng - JPMorgan Robert Burns - H.C.

06:52 04 Dec 2022 ALLO

Allogene Therapeutics (ALLO) Reports Q3 Loss, Lags Revenue Estimates

Allogene Therapeutics (ALLO) delivered earnings and revenue surprises of 6.45% and 45.56%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

08:30 04 Dec 2022 ALLO

Allogene Therapeutics to Report Third Quarter 2022 Financial Results on November 2, 2022

Conference Call and Webcast Scheduled for 2:00 PM PT/5:00 PM ET Conference Call and Webcast Scheduled for 2:00 PM PT/5:00 PM ET

03:26 04 Dec 2022 ALLO

Allogene: Possible First Pivotal Study With Allogeneic CAR-T ALLO-501A

Allogene has potential to have the first pivotal phase 2 study using its allogeneic CAR-T known as ALLO-501A for the treatment of patients with non-Hodgkin's Lymphoma. Trial results are to be released from several long-term follow-up studies including ALPHA, ALPHA2 and UNIVERSAL by end of 2022.

12:47 04 Dec 2022 ALLO

Allogene Therapeutics (ALLO) Down 10.9% Since Last Earnings Report: Can It Rebound?

Allogene Therapeutics (ALLO) reported earnings 30 days ago. What's next for the stock?

04:33 04 Dec 2022 ALLO

Allogene (ALLO) Q1 Earnings Beat, Pipeline Progressing Well

Allogene's (ALLO) second-quarter earnings beat estimates. ALLO is on track to initiate a pivotal phase II study on ALLO-501A in large B cell lymphoma in the coming weeks.

ALLO Financial details

Company Rating
Neutral
Market Cap
1.36B
Income
-312.65M
Revenue
161K
Book val./share
5.15
Cash/share
3.84
Dividend
-
Dividend %
-
Employees
356
Optionable
No
Shortable
Yes
Earnings
21 Feb 2023
P/E
-4.3
Forward P/E
-4.26
PEG
-7.45
P/S
8441.24
P/B
1.84
P/C
2.46
P/FCF
-6.53
Quick Ratio
11.3
Current Ratio
11.64
Debt / Equity
0.13
LT Debt / Equity
0.13
-
-
EPS (TTM)
-2.2
EPS next Y
-2.22
EPS next Q
-0.62
EPS this Y
2.65%
EPS next Y
0.91%
EPS next 5Y
0.91%
EPS last 5Y
-
Revenue last 5Y
-
Revenue Q/Q
-
EPS Q/Q
11.54%
-
-
-
-
SMA20
-
SMA50
-16.67%
SMA100
-16.67%
Inst Own
73.36%
Inst Trans
2.73%
ROA
-35%
ROE
-38%
ROC
-0.37%
Gross Margin
-
Oper. Margin
-194390%
Profit Margin
-194194%
Payout
-
Shs Outstand
143.81M
Shs Float
82.01M
-
-
-
-
Target Price
34.25
52W Range
6.43-19.11
52W High
-50.21%
52W Low
+57.67%
RSI
44
Rel Volume
0.35
Avg Volume
1.87M
Volume
654.51K
Perf Week
-10.75%
Perf Month
-5.96%
Perf Quarter
3.84%
Perf Half Y
19.29%
-
-
-
-
Beta
0.587211
-
-
Volatility
0.52%, 0.54%
Prev Close
0.96%
Price
9.46
Change
-3.76%

ALLO Financial Performance

Yearly Fundamentals Overview

Last date of statement is 2021-12-31

Metric History 2018-12-312019-12-312020-12-31 2021-12-31
Revenue per share
0000.32
Net income per share
-7.31-1.83-2.08-2.14
Operating cash flow per share
-1.54-1.36-0.96-1.54
Free cash flow per share
-1.65-1.86-1.5-1.71
Cash per share
15.875.256.883.8
Book value per share
24.296.228.977.61
Tangible book value per share
24.266.228.977.61
Share holders equity per share
24.296.228.977.61
Interest debt per share
1.3100.450.58
Market cap
877.14M2.24B4.18B1.28B
Enterprise value
819.16M2.06B4.05B1.17B
P/E ratio
-4.15-12.11-16.69-4.97
Price to sales ratio
00033.21
POCF ratio
-19.64-16.28-36.29-6.92
PFCF ratio
-18.32-11.88-23.07-6.2
P/B Ratio
1.253.553.871.39
PTB ratio
1.253.553.871.39
EV to sales
00030.53
Enterprise value over EBITDA
-3.96-10.46-16.68-4.77
EV to operating cash flow
-18.35-15-35.17-6.36
EV to free cash flow
-17.11-10.95-22.35-5.7
Earnings yield
-0.24-0.08-0.06-0.2
Free cash flow yield
-0.05-0.08-0.04-0.16
Debt to equity
0.0500.050.08
Debt to assets
0.090.120.120.12
Net debt to EBITDA
0.280.890.530.42
Current ratio
15.8916.468.969.78
Interest coverage
-57.43000
Income quality
0.210.740.460.72
Dividend Yield
0000
Payout ratio
0000
Sales general and administrative to revenue
0001.93
Research and developement to revenue
0005.72
Intangibles to total assets
0000
Capex to operating cash flow
0.070.370.570.12
Capex to revenue
000-0.56
Capex to depreciation
-2.16-10.1-8.69-2.05
Stock based compensation to revenue
0002.1
Graham number
63.1915.9920.4819.12
ROIC
-0.26-0.3-0.23-0.26
Return on tangible assets
-0.27-0.26-0.2-0.25
Graham Net
13.514.395.652.78
Working capital
438.52M511.5M750.81M423.15M
Tangible asset value
702.41M628.87M00
Net current asset value
397.29M455.8M696.92M349.1M
Invested capital
0.0500.050.08
Average receivables
0000
Average payables
11.36M9.82M10.39M10.32M
Average inventory
0000
Days sales outstanding
0000
Days payables outstanding
0000
Days of inventory on hand
0000
Receivables turnover
0000
Payables turnover
0000
Inventory turnover
0000
ROE
-0.3-0.29-0.23-0.28
Capex per share
-0.11-0.5-0.55-0.18

Quarterly Fundamentals Overview

Last date of statement is 2022-09-30 for Q3

Metric History 2021-09-302021-12-312022-03-312022-06-30 2022-09-30
Revenue per share
00000
Net income per share
-0.57-0.54-0.56-0.52-0.58
Operating cash flow per share
-0.36-0.33-0.48-0.3-0.33
Free cash flow per share
-0.38-0.33-0.5-0.31-0.33
Cash per share
3.533.293.183.423.84
Book value per share
7.086.586.055.595.15
Tangible book value per share
7.086.586.055.595.15
Share holders equity per share
7.086.586.055.595.15
Interest debt per share
0.370.50.490.690.68
Market cap
3.52B2.08B1.29B1.63B1.55B
Enterprise value
3.38B1.97B1.27B1.64B1.57B
P/E ratio
-11.26-6.93-4.03-5.46-4.67
Price to sales ratio
71.87K40.72K21.11K031.66K
POCF ratio
-72.05-45.7-18.87-38.43-32.56
PFCF ratio
-67.43-44.97-18.36-37.23-32.41
P/B Ratio
3.632.271.512.042.1
PTB ratio
3.632.271.512.042.1
EV to sales
69.02K38.69K20.86K032.12K
Enterprise value over EBITDA
-44.59-27.94-16.81-22.45-20.02
EV to operating cash flow
-69.2-43.43-18.64-38.48-33.03
EV to free cash flow
-64.76-42.73-18.14-37.28-32.87
Earnings yield
-0.02-0.04-0.06-0.05-0.05
Free cash flow yield
-0.01-0.02-0.05-0.03-0.03
Debt to equity
0.050.080.080.120.13
Debt to assets
0.10.120.110.150.17
Net debt to EBITDA
1.841.460.2-0.03-0.28
Current ratio
9.49.7812.7411.4211.64
Interest coverage
00-162.590-82.32
Income quality
0.630.610.850.570.57
Dividend Yield
00000
Payout ratio
00000
Sales general and administrative to revenue
387.73391.39326.180385.65
Research and developement to revenue
1.2K1.06K986.1601.3K
Intangibles to total assets
00000
Capex to operating cash flow
0.070.020.030.030
Capex to revenue
-68.31-14.43-31.180-4.55
Capex to depreciation
-1.44-0.17-0.52-0.37-0.06
Stock based compensation to revenue
425.63432.08365.820431.59
Graham number
9.538.938.778.18.19
ROIC
-0.08-0.07-0.09-0.08-0.1
Return on tangible assets
-0.07-0.07-0.08-0.08-0.09
Graham Net
2.732.412.42.42.82
Working capital
449.37M423.15M432.87M468.12M520.19M
Tangible asset value
00000
Net current asset value
393.55M349.1M360.34M367.33M421.45M
Invested capital
0.050.080.080.120.13
Average receivables
00000
Average payables
10.61M9.98M9.21M9.71M10.38M
Average inventory
00000
Days sales outstanding
00000
Days payables outstanding
00000
Days of inventory on hand
00000
Receivables turnover
00000
Payables turnover
00000
Inventory turnover
00000
ROE
-0.08-0.08-0.09-0.09-0.11
Capex per share
-0.02-0.01-0.01-0.010

ALLO Frequently Asked Questions

What is Allogene Therapeutics, Inc. stock symbol ?

Allogene Therapeutics, Inc. is a US stock , located in South san francisco of California and trading under the symbol ALLO

Is Allogene Therapeutics, Inc. buy or a sell ?

8 stock analysts have 8 predictions with a medium analyst target price of $34.25. The lowest prediction is $11 and the highest is $55

What is ALLO stock prediction ?

What is Allogene Therapeutics, Inc. stock quote today ?

Allogene Therapeutics, Inc. stock price is $9.46 today.

Is Allogene Therapeutics, Inc. stock public?

Yes, Allogene Therapeutics, Inc. is a publicly traded company.

Something similar

Top Correlated Stocks
Similar Market Cap